Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Press Release
Friday, May 15, 2015

Strides Arcolab receives ANDA approval from US FDA for Lamivudine and Zidovudine Tablets

Product to be launched immediately

Bangalore, May 15 2015, Strides Arcolab Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg**.

According to IMS data, the US market for Lamivudine and Zidovudine Tablets is approximately USD 120 million.

The product will be manufactured at the Company's Oral dosage facility at Bangalore and marketed by Strides in the US Market. The product will be launched in the markets immediately.

About Lamivudine and Zidovudine Tablets
Lamivudine and Zidovudine 150 mg/300 mg (generic version of generic version of Viiv's Combivir®) belong to a group of antiviral medicines, also known as antiretrovirals and is used with other antiretroviral medicines to treat HIV infection in adults and children. Lamivudine and Zidovudine 150 mg/300 mg Tablets reduces the amount of HIV in your body, and keeps it at a low level.

About Strides Arcolab Limited
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical Company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products. The Company has 8 manufacturing facilities presence in more than 75 countries in developed and emerging markets. Additional information is available at the Company's website at www.stridesarco.com. For further information, please contact:

Strides Arcolab Limited	**PR Consultancy – Fortuna PR**
Mohan Kumar, CEO - Pharma +91 80 6784 0748	K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.in
Vikesh Kumar +91 80 6784 0827 Kannan N +91 98450 54745	K Priya: +91 9535425418, priya@fortunapr.in